Events & News
We are so happy to get back out on the road! Although some conferences and events remain virtual, more and more are opening up and we are running back with open arms! We hope to see you soon!
Please see below for our events and news
OptumRx Requiring Consent to Share 340B Claims Data
According to a May 26 email to entities, pharmacy care services company OptumRx is requiring 340B covered entities to get consent before sharing OptumRx contract pharmacy claims data with drug manufacturers to satisfy manufacturers’ conditions on 340B pricing. The federal government told eight of the 16 companies who put conditions on 340B pricing that their policies are illegal. While seven drug manufacturers are suing to have the government’s decisions struck down, covered entities spending more and earning less due to the companies’ denials of 340B pricing are weighing whether to give in and supply the claims data. 340B provider groups told the government that providing claims data to a drug manufacturer or drug manufacturer third-party vendor will compromise patient privacy and puts their members at legal risk. To read more click here.
AstraZeneca Pricing Issues
In early April, 340Basics noticed a significant increase in issues with AstraZeneca drug pricing, seeing that AstraZeneca pushed a bad file to wholesalers to update their systems regarding pricing restrictions for our accounts. This caused accounts with exceptions to be blocked and sent to us at retail pricing instead of 340B pricing. The file was likely sent from AstraZeneca to wholesalers at the end of March/beginning of April. Price files for our accounts were incorrect as of 4/2, but wholesalers are indicating that the pricing is reflecting correctly on their end, likely meaning AstraZeneca corrected the errors with an updated file sent to wholesalers after 4/2. 340Basics has not seen all accounts updated with new files to confirm and are working to request updates on affected accounts ASAP. If you have an account affected by this and wish to ensure new files are received, please contact us here: https://340basics.com/contact-us/
Gilead Announces 340B Contract Pharmacy Restrictions
Gilead recently imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. The policy, which applies to hospital and grantee entities, comes in the same week that entities became aware of an apparent change in Gilead’s HIV drug reimbursement practices, giving contract pharmacies second thoughts on whether they want to continue to partner with 340B providers. Hospitals and grantees reported receiving a March 15 letter by email stating that starting May 2, 340B covered entities must provide claims level data for Gilead’s branded hepatitis C products to remain eligible for bill to/ship to orders for multiple contract pharmacies.